Search Results - chemotherapy

14 Results

Sort By:

Fatty-Acid Modified Cytotoxins and Peptides for Improved Efficacy, Safety, and Dosing Flexibility

SHORT DESCRIPTION A suite of four complementary technologies for a long-chain fatty‑acid–guided drug delivery platform to achieve superior therapeutic outcomes with reduced toxicity across both oncology and critical care applications. INVENTORS Nathan Gianneschi*, and others Weinberg College of Arts and Sciences,...

Published: 6/2/2026 | Updated: 6/1/2026 | Inventor(s):

Keywords(s): Adjunct therapy, BIO2026, Biologic, Breast cancer, Cancer/Oncology, Chemotherapy, Colon cancer, Lung cancer, Ovarian cancer, Pancreatic cancer, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Aqueous Formulations of Cytotoxic Taxanes with Cyclodextrin

NU 2022-109 INVENTORS Brittney Williams Matthew Thompson Nathan Gianneschi* SHORT DESCRIPTION This invention describes aqueous formulations of cytotoxic taxane drugs conjugated to fatty acids, solubilized using cyclodextrin inclusion complexes, providing water-soluble chemotherapy formulations that eliminate the need for toxic organic solvents...

Published: 6/16/2026 | Updated: 2/25/2026 | Inventor(s):

Keywords(s): BIO2026, Cancer/Oncology, Chemotherapy, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Modified Cytotoxins and their Therapeutic Use

NU 2022-111 INVENTORS Cassandra Callmann Matthew Thompson Clare LeGuyader Paul Bertin Nathan Gianneschi* SHORT DESCRIPTION This invention is for chemically modified small-molecule cytotoxic drugs conjugated to long-chain fatty acid-like hydrophobic moieties that bind non-covalently to albumin, creating improved cancer therapeutics with enhanced...

Published: 6/16/2026 | Updated: 2/24/2026 | Inventor(s):

Keywords(s): BIO2026, Cancer/Oncology, Chemotherapy, Small molecule, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Retinoic Acid Agonists for Attenuation of Doxorubicin-Induced Cardiotoxicity

SHORT DESCRIPTION A method for preventing cardiotoxicity in patients undergoing anthracycline-based chemotherapy using retinoic acid receptor gamma (RARG) agonists. INVENTORS Paul W Burridge*, PhD Associate Professor, Pharmacology, Northwestern University Feinberg School of Medicine * Principal Investigator NU...

Published: 2/6/2026 | Updated: 2/6/2026 | Inventor(s):

Keywords(s): Cancer Treatment, Cancer/Oncology, Cardiology and Cardiovascular disease, Chemotherapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Bioelectric Neuromodulation Methods for Hematopoiesis Regulation During Chemotherapy (Case No. 2020-382)

Summary: UCLA researchers in the Department of Bioengineering have developed an electrical neuromodulation method to accelerate recovery from deleterious chemotherapy side effects to improve patient outcome. Background: Chemotherapy works by targeting and killing fast-growing cancer cells using anti-cancer drugs. However, because these drugs lack...

Published: 4/29/2026 | Updated: 8/21/2025 | Inventor(s): Wentai Liu

Keywords(s): algorithmic cancer detection, Bladder Cancer, blood cancers, Brain cancer, Breast Cancer, Cancer, cancer antigen, cancer detection, Cancer Immunotherapy, cancer inhibition, cancer metabolism, Cancer stem cells, cancer target, castration resistant prostate cancer, Chemotherapy, head and neck cancer, lympathic cancers, lymphatic cancer, Mesenchymal Stem Cell Derived Cancer Cells, Neuromodulation, non-small cell lung cancer, Orthotopic cancer models, Pancreatic cancer, prostate cancer, small cell cancer, small cell lung cancer, small cell prostate cancer

Category(s): Medical Devices, Medical Devices > Neural Stimulation, Chemical, Electrical, Therapeutics, Therapeutics > Oncology

Interferon Activation Score Is a Biomarker for Immunotherapy in Malignant Glioma Patients (UCLA Case No. 2024-043)

UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant glioma patients receiving immunotherapy to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...

Published: 7/31/2025 | Updated: 10/23/2024 | Inventor(s): Robert Prins

Keywords(s): adjuvant therapy, Biomarker, Chemotherapy, Clinical Trial, dendritic cell vaccination, Glioblastoma, Glioma, immune response, Immunotherapy, interferon, malignant glioma

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Oncology, Therapeutics > CNS and Neurology

Neuro-Behavioral Assay for Physiological Evaluation of Water-Soluble Anesthetics

Background The development and use of general anesthetics is a key aspect of modern medicine. However, the current reliance on lipid-soluble general anesthetics presents issues, particularly for elderly patients who often have increased adipose tissue and decreased body water. This demographic can respond poorly to lipid-soluble anesthetics, resulting...

Published: 5/27/2026 | Updated: 1/17/2024 | Inventor(s): Gunther Zupanc, David Lehotzky

Keywords(s): Anesthesiology, Assays, Chemotherapy, Drug Discovery & Development, High Throughput Screening

Category(s): Technology Classifications > 1. Life Science, Technology Classifications > 1. Life Science > Drug Discovery

Targeted Epigenetic Editing as Novel Therapy for Malignant Glioma (UCLA Case No. 2023-047)

UCLA Researchers in the Department of Neurology/Neuro-Oncology and the David Geffen School of Medicine have developed methods for the Cas9-CRISPR mediated epigenetic targeting of malignant glioma, and which results in enhanced chemosensitivity to standard chemotherapeutic agents. BACKGROUND: Malignant gliomas are aggressive brain tumors originating...

Published: 10/7/2025 | Updated: 9/20/2023 | Inventor(s): Serendipity Rinonos, Albert Lai

Keywords(s): Brain, Cancer, Cancer stem cells, Chemotherapy, Combination therapy, CRISPR, CRISPR-Cas9, Epigenetics, GBM, Glioma

Category(s): Therapeutics > Oncology, Therapeutics > CNS and Neurology

Increased Therapeutic Effectiveness of PE-Based Immunotoxins

Abstract: Patients receiving immunotoxin cancer therapy are less likely to experience the deleterious side-effects associated with non-discriminate therapies such as chemotherapy or radiation therapy. Unfortunately, the continued administration of immunotoxins often leads to a reduced patient response due to the formation of neutralizing antibodies...

Published: 5/14/2025 | Updated: 8/2/2023 | Inventor(s): Ira Pastan, Masanori Onda, Wenhai Liu

Keywords(s): B-CELL, CHEMOTHERAPY, Human B cell epitopes, Immunogenic epitopes, Immunotoxin, Pseudomonas exotoxin A, T-cell

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues

Summary: NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents. Description of Technology: Topoisomerase enzymes play an important role in cancer progression by controlling changes...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Barry O'Keefe, Lauren Krumpe, Johan Rosengren, Ingrid Schroeder, Alan Bermingham, Christophe Marchand, Kirk Gustafson, Brice Wilson, Yves Pommier

Keywords(s): CANCER, Chemosensitizing Agents, CHEMOTHERAPY, Cyclic Peptide, Irinotecan TOP1, O’Keefe, Recifin, Tdp1, Topoisomerase 1 inhibitors, Topotecan, Tyrosyl-DNA Phosphodiesterase 1 Inhibitors

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Therapeutics

1 2